{
    "clinical_study": {
        "@rank": "139759", 
        "brief_summary": {
            "textblock": "Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first\n      episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Compare the rates and\n      severity of adverse effects using dapsone versus trimethoprim - sulfamethoxazole (TMP /\n      PurposeX). Establish relative toxicities with regard to suitability for outpatient\n      treatment."
        }, 
        "brief_title": "A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Requirement for other medications found to be effective in the treatment of\n             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).\n\n        Patients with the following are excluded:\n\n          -  History of allergic reaction to dapsone.\n\n          -  Requirement for other medications found to be effective in the treatment of\n             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).\n\n          -  Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive\n             will be withdrawn from the study and treated with another regimen.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Requirement for other medications found to be effective in the treatment of\n             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).\n\n        Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from\n        the study and treated with another regimen.\n\n        Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP)\n        documented by GIEMSA or methenamine stain.\n\n          -  Patients must:\n\n          -  Be willing and able to give informed consent.\n\n          -  Be expected to survive 1 week without therapy.\n\n          -  Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for\n             this episode."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002283", 
            "org_study_id": "007A"
        }, 
        "intervention": [
            {
                "intervention_name": "Trimethoprim", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Sulfamethoxazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Dapsone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dapsone", 
                "Trimethoprim", 
                "Trimethoprim-Sulfamethoxazole Combination", 
                "Sulfamethoxazole"
            ]
        }, 
        "keyword": [
            "Trimethoprim-Sulfamethoxazole Combination", 
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Dapsone", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "Jacobus Pharmaceutical Co"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002283"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jacobus Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1989"
    }, 
    "geocoordinates": {
        "Jacobus Pharmaceutical Co": "40.366 -74.679"
    }
}